CN100536865C - Application of Herba Solidaginis in preparing medicine for preventing and treating AIDS virus - Google Patents
Application of Herba Solidaginis in preparing medicine for preventing and treating AIDS virus Download PDFInfo
- Publication number
- CN100536865C CN100536865C CNB2006101271504A CN200610127150A CN100536865C CN 100536865 C CN100536865 C CN 100536865C CN B2006101271504 A CNB2006101271504 A CN B2006101271504A CN 200610127150 A CN200610127150 A CN 200610127150A CN 100536865 C CN100536865 C CN 100536865C
- Authority
- CN
- China
- Prior art keywords
- aids
- medicine
- herba solidaginis
- virus
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 241000725303 Human immunodeficiency virus Species 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000011550 stock solution Substances 0.000 claims abstract description 9
- 241000700605 Viruses Species 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 10
- 239000010231 banlangen Substances 0.000 claims description 10
- 238000007796 conventional method Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 7
- 239000006196 drop Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- -1 electuary Substances 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 3
- 239000003085 diluting agent Substances 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 241000607059 Solidago Species 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 19
- 230000007423 decrease Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 7
- 230000001629 suppression Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000245240 Lonicera Species 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the application of Solidago decurense in the preparation of the medicine used to treat or prevent AIDS. Pharmacodynamics has proved that the traditional Chinese medicine stock solution extracted from the Solidago decurense has an obvious activity against AIDS. So producers can add different diluents bases, adjuvants or bearers to the extracts to get materials in different dosage forms which can be applied in the medicines used to treat or prevent the AIDS.
Description
Technical field
The present invention relates to a kind of new purposes of pure botanical herbs preparation, specifically, the present invention relates to the application of Herba Solidaginis in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS.
Background technology
Acquired immune deficiency syndrome (AIDS) is from finding to be less than 20 years so far, but it in the whole world caused being widely current, more than 3,860 ten thousand people are infected, 2,500 ten thousand people have lost life.At present, have ten thousand every day in the world surplus the people newly infect HIV (human immunodeficiency virus) (Human Immunodeficiency Virus).Not only medical circle is in the research prophylactic treatment acquired immune deficiency syndrome (AIDS) of trying one's best, and national governments, all orders of society have also all dropped into the motion to anti-AIDS one after another.But up to the present, we mankind also do not find a kind of this sick active drug for the treatment of.The common view of acquired immune deficiency syndrome (AIDS) brainstrust in the 16th world's acquired immune deficiency syndrome (AIDS) conference is that the acquired immune deficiency syndrome (AIDS) scientific research field lacks the substantive breakthroughs that can retrieve a hopeless situation, makes us anxiety.Thereby the active drug of the research treatment and (AIDS) virus that prevents AIDS becomes very urgent.
Summary of the invention
The present invention is in order to treat and prevent AIDS (AIDS) virus, effectively kills and suppresses acquired immune deficiency syndrome (AIDS) (AIDS) virus, and the ultimate principle of utilization motherland Chinese materia medica has proposed the application of Herba Solidaginis in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS.
The application of Herba Solidaginis in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, described medicine is to make by comprising following weight percentages: Herba Solidaginis 50～100%.
Described medicine is to be made by described single raw material: described single raw material Herba Solidaginis and water are boiled and boiled 10～30 minutes by weight puts into diffuser for the ratio of 1:50～100, filter purification according to a conventional method and obtain described Chinese medicine stock solution.
Described Chinese medicine stock solution is made oral liquid or electuary through conventional purification.
Described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Radix Glycyrrhizae 10～50%.
Described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Flos Lonicerae 5～25%, Radix Isatidis 5～25%.
The application of Herba Solidaginis in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, described medicine is to make electuary, capsule or the prepared slices of Chinese crude drugs by the raw material that contains Herba Solidaginis through micronizing, and the weight percent content of Herba Solidaginis is 50～100%.
Described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Radix Glycyrrhizae 10～50%.
Described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Flos Lonicerae 25%, Radix Isatidis 25%.
The application of Herba Solidaginis in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, be to carry out the extraction separation purification by the raw material that contains Herba Solidaginis through the supercritical carbon dioxide extraction technology to make injection, electuary, spray, capsule or drop pill, the weight percent content of Herba Solidaginis is 50～100%.
Described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Radix Glycyrrhizae 10～50%.
Described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Flos Lonicerae 5～25%, Radix Isatidis 5～25%.
Described raw material Herba Solidaginis is selected the herb Herba Solidaginis for use.
Conventional purification process is roughly:
(1) lixiviating solution purification technique equipment commonly used: be settling tank or centrifuge and ultrafilter, ultrafilter membrane etc.
(2) technical process: settlement separate technology is to sink to making it principle with fluid separation applications naturally according to the gravity of solid particle own in liquid medium, the water extract put leave standstill certain hour in the settling tank, draw supernatant liquid with siphonage, also can adopt cooling in case of necessity and with the method for sedimentation agent-electrolyte (as Alumen) to reach efficient, fine purpose.
Existing micronizing wall breaking technology:
Finish by Shanghai Communications University's Onlly natural drug engineering company limited exploitation manufacturing " jet mill " nanoscale pulverizing, breaking cellular wall one gas synthesis device.Its principle: after raw material enters Jet Mill, in pulverizing chamber, there are several to pulverize nozzle, the nozzle supersonic airstream makes comminuting matter be subjected to the air-flow high speed impact and powder runs foul of each other, because air velocity is fast, the big crushing effect of impact force reaches the purpose that 0.5～10 micron particle (500 nanometers～10000 nanometers) reaches physical wall breaking simultaneously, makes human body can be absorbed with effective substance fully.
Supercritical CO
2The fluid extraction new technique:
It is strong to make " 1000L automatization large and super-critical unit " extracting power by the exploitation of east, Shenyang space group, extraction ratio height, quality controllable system.Its principle: CO
2Critical temperature and critical pressure be respectively 31.05 ℃ and 7.38MPa, when being in this critical point when above, the CO of this moment
2Have gas and liquid double grading simultaneously.It both had been similar to gas, and viscosity and gas are close; Be similar to liquid again, density and liquid are close, but its diffusion coefficient is more much bigger than liquid.Be an excellent solvent, can be by intermolecular interaction and diffusion with many substance dissolves.Simultaneously, in the zone of a little higher than critical point, pressure changes slightly, promptly causes the great changes of its density, thereby causes the bigger variation of dissolubility.Therefore, supercritical CO
2Can from matrix, substance dissolves be come out, form supercritical CO
2The load phase reduces the pressure or the elevated temperature of carrier gas, supercritical CO then
2Dissolubility reduce, these materials just are precipitated out (parsing) and CO
2Separate, thereby reach the purpose of extraction separation.
The using method of medicine of the present invention and effective dose are:
Described Chinese medicine stock solution is drunk dosage and is, adult every day two～four times, each 100～300ml.Described oral liquid, adult every day two～four times, each 10～20ml.
Described electuary, capsule or decoction pieces, adult every day three～four times, each 2～6 grams.
Described injection, adult's secondary every day, each 5～10ml.
Described drop pill, adult every day three times, each 8 balls.
Described spray is sprayed on the oral cavity, and every day for several times.
The 8-9 page of record of " Chinese medicine voluminous dictionary " (first volume) (the new medical college in Jiangsu is compiled): described Herba Solidaginis is a feverfew, its herb of general using or whole herb with root.Nature and flavor are arduous, cool.The herb Herba Solidaginis contains phenolic constituent, tannin, volatile oil, Saponin, flavonoid etc.Function cures mainly wind and heat dispersing, subduing swelling and detoxicating, headache due to common cold, laryngopharynx swelling and pain, jaundice, pertussis, infantile convulsion, traumatic injury, carbuncle carbuncle on the back, fungal infection of hand and foot.Staphylococcus aureus, streptococcus pneumoniae, bacillus pyocyaneus, dysentery bacterium etc. are all had significantly kill and inhibitory action.
Herba Solidaginis drug effect wind and heat dispersing, eliminating inflammation and expelling toxin; Pharmacology is gone into liver, gallbladder meridian; Property of medicine cold.
Radix Glycyrrhizae eliminating fire and detoxication, nourishing the lung to arrest cough; The pharmacology twelve channels and collaterals that passes through; Gentle, the coordinating the actions of various ingredients in a prescription of the property of medicine.
Flos Lonicerae drug effect heat-clearing and toxic substances removing, anti-inflammatory analgetic; Pharmacology is gone into lung, stomach, large intestine channel; The property of medicine is cold.
Radix Isatidis drug effect removing heat from blood relieves inflammation or internal heat eliminating inflammation and expelling toxin; Pharmacology is gone into the heart, lung meridian; The property of medicine is cold.
Herba Solidaginis and Radix Glycyrrhizae compatibility can be in harmonious proportion the Herba Solidaginis property of medicine, have strengthened the adaptability of medicine.
Herba Solidaginis and Flos Lonicerae, Radix Isatidis compatibility can improve attending effectiveness, increase the universal of medicine.
Study for many years and Inst. of Tropical Medicine, Guangzhou Chinese Medicine College's described Chinese medicine stock solution of acquired immune deficiency syndrome (AIDS) research center laboratory proofing has tangible AIDS virus resisting effect through the inventor.
Chinese medicine of the present invention is by the requirement of double blinding the plant Herba Solidaginis to be added water 1:120 ratio to extract the concentration time by decocting again, and the specimen that is made into HH2A (decocting 10 minutes) and two parts of micro-concentrations of HH2B (decocting 30 minutes) is delivered the pharmacodynamic study that acquired immune deficiency syndrome (AIDS) strain SIV virus is done in Inst. of Tropical Medicine, Guangzhou Chinese Medicine College acquired immune deficiency syndrome (AIDS) research center.
Anti-AIDS strain SIV in vitro tests is reported as follows:
The censorship date; On 03 24th, 2006
Reporting date: on 05 25th, 2006
The censorship unit: lotus Sector East 17-3-1-601 is adopted in the Hangzhou, Zhejiang province city
Censorship specimen: medicinal liquid HH2A, HH2B.
Censorship purpose: the activity that detects the anti-SIVmac test tube of censorship medicinal liquid sample with SIVmac-CEM * 174 systems.
One, material
1, cell line: CEM * 174 derive from U.S. Aarond Diamond acquired immune deficiency syndrome (AIDS) research center, and Beijing medical courses in general institute laboratory animal is represented.
2, strain: SIVmac derives from U.S. Aarond Diamond acquired immune deficiency syndrome (AIDS) research center, and Beijing medical courses in general institute laboratory animal is represented.
3, cell culture fluid: contain 10% calf serum RPMI1640 culture fluid.
4, testing sample: medicinal liquid HH2A, HH2B.
5, positive control drug: AZT is produced by CALBIOCHEM, specializes in test and uses.
6, anti-monkey IgG fluorescence: E.Y. produces.
7, anti-SIV monkey positive serum: SIV infected monkey convalescent serum.
8, other: 96 porocyte culture plates, 24 well culture plates.
Two, experimental technique
1, testing sample is to the toxicity test of CEM * 174 cell lines:
(1) dilution of testing sample: based on the testing sample original content, the experiment before with 10% calf serum RPMI1640 culture fluid with 10 times of drug dilutions.
(2) to the Cytotoxic mensuration in CEM * 174, medicine thinks that 10 times of diluents do 2 times of dilutions of series, i.e. 1:10,1:20,1:40,1:80,1:160,1:320,1:640,1:1280.Each testing sample that dilution is good adds 96 porocyte culture plates, the 100ul/ hole.Add 3.0 * 10
5The CEM of/ml * 174 cells, the 100ul/ hole.Put 37 ℃, 5%co2 saturated humidity incubator is cultivated, 4 days observed results.
(3) the toxicity test result judges.See Table 1
The toxicity judgment basis: with cell death and cell growing state serves as according to judging, " ++ ++ " in the table, " +++", " ++ ", "+" and "-" represent respectively:
" ++ ++ ": plant all death of cell of going into;
" +++": plant the most of death of the cell of going into, a few cell has temporary division:
" ++ ": it is about 50% that proliferating cells is less than cell control well, and dead cell is more;
"+": proliferating cells is less than cell control well about 25%;
"-": the cell well-grown, compare no significant difference with cell control well.
Table 1 HH2A, HH2B toxicity test result
| 1∶10 1∶20 1∶40 1∶80 1： 1: 1: 1: 1: 1: 160 320 640 1280 5120 10240 |
| HH2A++ + - - - - - - - - |
| HH2B+ - - - - - - - - - |
| The cell contrast--------- |
2, formal test: carry out with 24 orifice plates, every all with multiple hole.Test repeats 2 times.
(1) medicine is with the non-toxic concn serial dilution, and virus is by the test requirements document dilution, and cell is mixed with 3 * 10
5/ ml single cell suspension, each hole adds each reagent (medicine, virus, cell, culture fluid) by the listed order of table 2, and other establishes AZT positive drug and SIV control wells.Put 37 ℃, 5%CO2, the saturated humidity incubator changed once former dilution factor medicinal liquid in 3 days, treated that SIV control wells CPE occurred in 6-7 days ++ +～++ ++ the time measurement result.
(2) pathological changes (CPE) is observed in bread board earlier, and culture supernatant is made 2 times of serial dilutions and come the titration virus titer, calculates viral yield decline number, remaining cell is washed twice with PBS, smear calculates fluorescencepositive cell number, i.e. virus antigen positive cell number with indirect immunofluorescence.
Each hole application of sample situation of table 2 formal test
| AZT positive control hole, medicine hole SIV control wells |
| Medicine 0.8ml to be measured--- |
| AZT(2μM) — 0.8ml — |
| SIV(10TCID 50) 0.4ml 0.4ml 0.4ml |
| CEM×174(3×10 5) 0.4ml 0.4ml 0.4ml |
| Culture fluid---0.8ml |
(3) result judges index:
2) viral yield descends with log10 calculating, and test hole is compared with the virus control hole.As 1 dilution factor of test hole virus titer decline, i.e. viral yield decline 0.3log10, as 2 dilution poison of virus titer decline, i.e. viral yield decline 0.6log10, surplus to analogize.For example: the test hole virus titer is 1:320, and the virus control hole is 1:2560, then judges test hole viral yield decline 0.9log10.
3) cytopathy (CPE), fused cell, every visual field≤25%, for+; Every visual field≤50%, for ++; Every visual field≤75%, for +++; Every visual field〉75%, for ++ ++.
4) result judges
With the fluorescencepositive cell suppression ratio, viral yield descends mutually with reference to judging that the cytopathy degree is only for referencial use.Unrestraint: fluorescencepositive cell suppression ratio＜30%, viral yield decline＜0.6log10
The slight inhibition: fluorescencepositive cell suppression ratio 〉=30%, viral yield decline 〉=0.6log10;
Moderate suppresses: fluorescencepositive cell suppression ratio 〉=50%, viral yield decline 〉=1.2log10;
Highly suppress: fluorescencepositive cell suppression ratio 〉=60%, viral yield decline 〉=2.1log10;
Three, result of the test:
See Table 3
The external anti-SIV virus result of the test of table 3.HH2A, HH2B
| The thin virus titer cell drug of actual concentrations virus antigen dilution factor (μ g) born of the same parents' suppression ratio decline pathological changes is % (log10) as a result |
| 1:40-51.8 0.6 ++, +++slightly suppress HH2A 1:160-27.8 0.6 ++ ++ unrestraint |
| 1:10-49.9 1.21 +++moderate suppresses HH2B 1:40-17.4 0.6 ++ ++ unrestraint |
| AZT 2 μ M 89.3 2.71+highly suppress |
From showing the result, test sample HH2A has the effect of slight vitro inhibition SIV after through 40 times of dilutions, but has then lost the effect of anti-SIV when down 4 times of redilution are to 1:160; HH2B is that CEM * 174 cells are had slight toxic action in 1:10 concentration, and this concentration also shows the effect near the anti-SIV of moderate, but the not anti-dilution of this medicinal liquid has then lost the effect of anti-SIV when 1:40 concentration.
Research conclusion: according to above-mentioned experiment, as long as the proportioning of Herba Solidaginis and water is down successively decreased from 1:120, or change extracting mode as adopting present state-of-the-art supercritical carbon dioxide extraction new technique, just can obtain the extracting solution of high concentration, obtain the effect of realistic ideal anti-AIDS (AIDS) virus.Thereby reach the purpose of treatment and prevent AIDS (AIDS).
The specific embodiment
Further specify the present invention with embodiment below.
Example 1
100 gram Herba Solidaginiss and 5000ml water are put into diffuser boil and boil 10 minutes, can obtain described Chinese medicine stock solution 4800ml.Filtering and concentrating is mixed with oral liquid or makes electuary according to a conventional method.
Example 2
100 gram Herba Solidaginiss and 10000ml water are put into diffuser boil and boil 25 minutes, obtain described Chinese medicine stock solution 9500ml.Filtering and concentrating is mixed with oral liquid or makes electuary according to a conventional method.
Example 3
90 gram Herba Solidaginiss and 10 gram Radix Glycyrrhizaes and 5000ml water are put into diffuser boil and boil 30 minutes, filtration can obtain described Chinese medicine 4400ml.
Example 4
50 gram Herba Solidaginiss and 25 gram Flos Loniceraes 25 gram Radix Isatidis and 5000ml water are put into diffuser boil and boil 30 minutes, filtration can obtain described Chinese medicine 4400ml.
Example 5
100 gram Herba Solidaginiss are made electuary of the present invention, capsule or drink according to a conventional method after micronizing.
Example 6
90 gram Herba Solidaginiss and 10 gram Radix Glycyrrhizaes are made electuary of the present invention, capsule or decoction pieces according to a conventional method after micronizing.
Example 7
50 gram Herba Solidaginiss, 25 gram Flos Loniceraes, 25 gram Radix Isatidis are made electuary of the present invention, capsule or decoction pieces according to a conventional method after micronizing.
Example 8
With 100 gram Herba Solidaginiss through according to a conventional method through supercritical CO
2Make injection of the present invention, electuary, spray, capsule or drop pill behind the fluid extraction.
Example 9
90 gram Herba Solidaginiss and 10 are restrained Radix Glycyrrhizaes according to a conventional method through supercritical CO
2Make injection of the present invention, electuary, spray, capsule or drop pill behind the fluid extraction.
Example 10
50 gram Herba Solidaginiss, 25 gram Flos Loniceraes, 25 are restrained Radix Isatidis according to a conventional method through supercritical CO
2Make injection of the present invention, electuary, spray, capsule or drop pill behind the fluid extraction.
Claims (10)
1. the application of Herba Solidaginis in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, described medicine is to make by comprising following raw material medicines in percentage by weight: Herba Solidaginis 50～100%.
2. the application of Herba Solidaginis according to claim 1 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, it is characterized in that described medicine is that described Herba Solidaginis and water are boiled and boil 10～30 minutes by weight puts into diffuser for the ratio of 1:50-100, filters purification according to a conventional method and obtains described Chinese medicine stock solution.
3. the application of Herba Solidaginis according to claim 2 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS is characterized in that described Chinese medicine stock solution is through concentrated oral liquid or the electuary made of conventional purification.
4. the application of Herba Solidaginis according to claim 1 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, described raw material Herba Solidaginis is selected the herb Herba Solidaginis for use.
5. the application of Herba Solidaginis according to claim 1 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS is characterized in that described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Radix Glycyrrhizae 10～50%.
6. the application of Herba Solidaginis according to claim 1 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS is characterized in that described medicine is to be made by following weight percentages; Herba Solidaginis 50～90%, Flos Lonicerae 5～25%, Radix Isatidis 5～25%.
7. the application of Herba Solidaginis according to claim 1 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, it is characterized in that described medicine is to make electuary, capsule or the prepared slices of Chinese crude drugs by the raw material that contains Herba Solidaginis after micronizing, the weight percent content of Herba Solidaginis is 50～100%.
8. the application of Herba Solidaginis according to claim 7 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS is characterized in that described medicine is to be made by following weight percentages, Herba Solidaginis 50-90%, Radix Glycyrrhizae 10～50%.
9. the application of Herba Solidaginis according to claim 7 in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS, it is characterized in that described medicine is to be made by following weight percentages: Herba Solidaginis 50～90%, Flos Lonicerae 5～25%, Radix Isatidis 5～25%.
10. the application of Herba Solidaginis in the medicine of the preparation treatment and (AIDS) virus that prevents AIDS is characterized in that described medicine is through supercritical CO by the raw material that contains Herba Solidaginis
2Make injection, electuary, spray, capsule or drop pill behind the fluid extraction, the weight percent content of Herba Solidaginis is 50～100%.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101271504A CN100536865C (en) | 2006-09-07 | 2006-09-07 | Application of Herba Solidaginis in preparing medicine for preventing and treating AIDS virus |
| EP07763992A EP2065049A4 (en) | 2006-09-07 | 2007-07-06 | The use of solidago virgaurea in the preparation of a medicament for treatment and prevention of a virus |
| JP2009526997A JP2010502655A (en) | 2006-09-07 | 2007-07-06 | Application of Solidago radish in the preparation of drugs for antiviral treatment and prevention |
| PCT/CN2007/002084 WO2008031315A1 (en) | 2006-09-07 | 2007-07-06 | The use of solidago virgaurea in the preparation of a medicament for treatment and prevention of a virus |
| US11/970,589 US20080102140A1 (en) | 2006-09-07 | 2008-01-08 | Use of solidago virgaurea in the treatment and prevention of viral infections |
| US12/781,041 US20100221367A1 (en) | 2006-09-07 | 2010-05-17 | Use of solidago virgaurea in the treatment and prevention of viral infections |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101271504A CN100536865C (en) | 2006-09-07 | 2006-09-07 | Application of Herba Solidaginis in preparing medicine for preventing and treating AIDS virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1927245A CN1927245A (en) | 2007-03-14 |
| CN100536865C true CN100536865C (en) | 2009-09-09 |
Family
ID=37857475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101271504A Expired - Fee Related CN100536865C (en) | 2006-09-07 | 2006-09-07 | Application of Herba Solidaginis in preparing medicine for preventing and treating AIDS virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100536865C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010099613A1 (en) * | 2009-03-03 | 2010-09-10 | Viva Pharmaceutical Inc. | Plant extract compositions for prevention and treatment of influenza |
| JP2013508309A (en) * | 2009-10-22 | 2013-03-07 | バイオファーマコパ インコーポレイティド | Herbic compositions comprising ginger and ginkgo biloba for the treatment of colds and flu |
| CN113041289B (en) * | 2021-04-20 | 2022-08-09 | 贵州中医药大学 | Compound goldenrod spray dry powder anti-RNA virus drug target activity and application |
-
2006
- 2006-09-07 CN CNB2006101271504A patent/CN100536865C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 一枝黄花属植物化学成分和药理活性研究. 姜涛等.中西医结合学报，第4卷第4期. 2006 |
| 一枝黄花属植物化学成分和药理活性研究. 姜涛等.中西医结合学报，第4卷第4期. 2006 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1927245A (en) | 2007-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106265830A (en) | Conception control gel | |
| CN100536865C (en) | Application of Herba Solidaginis in preparing medicine for preventing and treating AIDS virus | |
| CN102836200A (en) | Application of oil orange to preparation of anti-H1N1 flu medicament | |
| KR20220156604A (en) | Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection | |
| US20030054047A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
| CN1931208B (en) | Application of common goldenrod herb in preparing medicine for preventing and treating H5N1 bird flu and influenza | |
| CN105233144A (en) | Traditional Chinese medicine preparation for treating dermatomycoses of animals and preparation method of traditional Chinese medicine preparation | |
| US20080102140A1 (en) | Use of solidago virgaurea in the treatment and prevention of viral infections | |
| CN104804056A (en) | Sarcopyramis nepalensis extract and application thereof | |
| CN113616764B (en) | Antiviral traditional Chinese medicine composition and application thereof | |
| CN101269100A (en) | Application of goldenrod in preparing medicament for treating and preventing cancer | |
| CN107334793A (en) | The purposes of wintersweet platymiscium helicobacter pylori resistant | |
| CN113577187A (en) | Anti-influenza traditional Chinese medicine composition, traditional Chinese medicine extract and preparation method and application thereof | |
| CN1291730C (en) | Chinese medicine for preventing and treating SARS virus | |
| CN102198192A (en) | Traditional Chinese medicine composition for treating HINI and application thereof | |
| CN112516276A (en) | Traditional Chinese medicine for preventing novel coronavirus pneumonia, preparation process thereof and traditional Chinese medicine beverage | |
| CN101214325B (en) | Method for preparing compound 'chenxiangwei'medicine and new use thereof | |
| CN103585291B (en) | Application of herba delphinii extract in preparation of drugs treating AIDS | |
| CN103585212B (en) | The application of Dorema ammoniacum resin extract in preparation treatment AIDS-treating medicine | |
| CN102614467A (en) | Traditional Chinese medical composition for treatment of acquired immunodeficiency syndrome and preparation method and application thereof | |
| CN100387248C (en) | Bone consumption powdered injection and its preparation method | |
| KR101899122B1 (en) | Pharmaceutical composition for preventing or treating hepatitis C virus infectious disease | |
| CN104173426A (en) | Traditional Chinese medicine composition with liver-protecting function, as well as preparation method and application thereof | |
| CN103585259B (en) | The application of a kind of Mucuna birdwoodiana Tutcher extract in preparation treatment AIDS-treating medicine | |
| CN111671860A (en) | Antiviral traditional Chinese medicine compound preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090909 |